Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Arrevus logo — Conquering antibiotic resistance by targeting critical disea...

Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.

Founded 2015 Grant Total: $2.05M Biotechnology, Pharmaceutical

General Information

Company Name Arrevus
Founded Year 2015
Industries Biotechnology, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Arrevus. To contact Arrevus, visit arrevus.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arrevus compare?

A PDF of Arrevus and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arrevus soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arrevus

Arrevus is a biotechnology and pharmaceutical startup, founded in 2015, with a mission to address antibiotic resistance in critical diseases. The company's focus lies in developing Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs) for diseases where antibiotic resistance has significant clinical implications and limited treatment options. With their slogan "Conquering antibiotic resistance by targeting critical diseases with innovative DPCs," Arrevus aims to combat the impact of antibacterial resistance on patient health outcomes. Their last investment of $800.00K came in the form of a grant from the U.S. Department of Defense on 29 May 2020. Arrevus stands out for its dedication to addressing a pressing issue in the medical field and its strategic approach to drug development, positioning it as an impactful player in the fight against antibiotic resistance.

Business keywords: antibiotic resistance, DPCs, drug development, clinical implications, bacterial resistance, MRSA, antimicrobial peptides, life-threatening diseases, patient outcomes, innovative therapies, pharmaceutical research, biomedical innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $800.00K 1
U.S. Department of Defense
29 May 2020
Debt Financing $250.00K 1
North Carolina Biotechnology Center
16 Oct 2019
Venture Round $1.00M -
26 May 2017

Arrevus Alternatives & Competitors

View All Alternatives
Arrevus vs
Arpida
Arpida

Arpida (SIX: ARPN) is a biopharmaceutical company headquartered in Reinach, near Basel, Switzerland...

Private Equity
31 employees
Biopharma, Biotechnology
Arrevus vs
Bugworks Research Inc.
Bugworks Research Inc. India

Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology.

Venture round
46 employees
Biotechnology, Health Care
Arrevus vs
Clarametyx Biosciences
Clarametyx Biosciences United States

Targeting biofilms to treat chronic respiratory disease

Series A
23 employees
Biotechnology, Health Care
View all alternatives

FAQ About Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.
Arrevus was founded in 2015.
Arrevus operates in Biotechnology and Pharmaceutical. Its work centres on antibiotic resistance, DPCs, drug development and clinical implications.
Arrevus has completed 3 funding rounds, raising a total of $2.05M. The latest funding stage is Grant.
Top alternatives and competitors to Arrevus include Arpida, Bugworks Research Inc., Clarametyx Biosciences, Phico Therapeutics Ltd., PolyPid Ltd. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arrevus and Arpida are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arrevus, https://bouncewatch.com/company/arrevus, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes